OpGen (OPGN) Set to Announce Quarterly Earnings on Thursday

OpGen (NASDAQ:OPGN) will post its quarterly earnings results on Thursday, April 4th.

OpGen Price Performance

OpGen stock traded up $0.02 during trading hours on Wednesday, hitting $0.64. The company had a trading volume of 478,683 shares, compared to its average volume of 1,630,438. The firm has a 50-day moving average of $0.47 and a 200 day moving average of $0.47. The firm has a market cap of $6.41 million, a PE ratio of -0.10 and a beta of -0.71. OpGen has a one year low of $0.17 and a one year high of $3.84.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on OpGen in a research note on Friday, March 29th. They set a “sell” rating on the stock.

Institutional Trading of OpGen

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP bought a new position in shares of OpGen in the first quarter worth $49,000. Citadel Advisors LLC lifted its stake in shares of OpGen by 571.0% in the 3rd quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85,754 shares during the last quarter. HRT Financial LP acquired a new stake in OpGen during the 4th quarter worth approximately $26,000. Finally, Vanguard Group Inc. grew its position in shares of OpGen by 39.8% in the 3rd quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock valued at $537,000 after buying an additional 534,960 shares during the last quarter. Institutional investors and hedge funds own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.